Wilson Sonsini advised Apexigen on the deal. Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Regor Therapeutics on the deal. Eli Lilly and Company and Regor Therapeutics Group entered into a multi-year research collaboration and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the deal. ALX Oncology Holdings Inc. (ALX Oncology), a clinical-stage immuno-oncology company, and ScalmiBio, Inc., announced that...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
You must be a Standard 1 Year member to access this content.
